We report here the identification of a ligand-receptor system that, upon engagement, leads to the establishment of an antiviral state. Three closely positioned genes on human chromosome 19 encode distinct but paralogous proteins, which we designate interferon-lambda1 (IFN-lambda1), IFN-lambda2 and IFN-lambda3 (tentatively designated as IL-29, IL-28A and IL-28B, respectively, by HUGO). The expression of IFN-lambda mRNAs was inducible by viral infection in several cell lines. We identified a distinct receptor complex that is utilized by all three IFN-lambda proteins for signaling and is composed of two subunits, a receptor designated CRF2-12 (also designated as IFN-lambdaR1) and a second subunit, CRF2-4 (also known as IL-10R2). Both receptor chains are constitutively expressed on a wide variety of human cell lines and tissues and signal through the Jak-STAT (Janus kinases-signal transducers and activators of transcription) pathway. This receptor-ligand system may contribute to antiviral or other defenses by a mechanism similar to, but independent of, type I IFNs.
Rhinoviruses are the major cause of asthma exacerbations, and asthmatics have increased susceptibility to rhinovirus and risk of invasive bacterial infections. Here we show deficient induction of interferon-lambdas by rhinovirus in asthmatic primary bronchial epithelial cells and alveolar macrophages, which was highly correlated with severity of rhinovirus-induced asthma exacerbation and virus load in experimentally infected human volunteers. Induction by lipopolysaccharide in asthmatic macrophages was also deficient and correlated with exacerbation severity. These results identify previously unknown mechanisms of susceptibility to infection in asthma and suggest new approaches to prevention and/or treatment of asthma exacerbations.
Lambda interferons (IFNλs) or type III IFNs share homology, expression patterns, signaling cascades, and antiviral functions with type I IFNs. This has complicated the unwinding of their unique non-redundant roles. Through the systematic study of influenza virus infection in mice, we herein show that IFNλs are the first IFNs produced that act at the epithelial barrier to suppress initial viral spread without activating inflammation. If infection progresses, type I IFNs come into play to enhance viral resistance and induce pro-inflammatory responses essential for confronting infection but causing immunopathology. Central to this are neutrophils which respond to both cytokines to upregulate antimicrobial functions but exhibit pro-inflammatory activation only to type I IFNs. Accordingly, Ifnlr1 mice display enhanced type I IFN production, neutrophilia, lung injury, and lethality, while therapeutic administration of PEG-IFNλ potently suppresses these effects. IFNλs therefore constitute the front line of antiviral defense in the lung without compromising host fitness.
The discovery and initial description of the interferon-l (IFN-l) family in early 2003 opened an exciting new chapter in the field of IFN research. There are 3 IFN-l genes that encode 3 distinct but highly related proteins denoted IFN-l1, -l2, and -l3. These proteins are also known as interleukin-29 (IL-29), IL-28A, and IL-28B, respectively. Collectively, these 3 cytokines comprise the type III subset of IFNs. They are distinct from both type I and type II IFNs for a number of reasons, including the fact that they signal through a heterodimeric receptor complex that is different from the receptors used by type I or type II IFNs. Although type I IFNs (IFN-a/b) and type III IFNs (IFN-l) signal via distinct receptor complexes, they activate the same intracellular signaling pathway and many of the same biological activities, including antiviral activity, in a wide variety of target cells. Consistent with their antiviral activity, expression of the IFN-l genes and their corresponding proteins is inducible by infection with many types of viruses. Therefore, expression of the type III IFNs (IFN-ls) and their primary biological activity are very similar to the type I IFNs. However, unlike IFN-a receptors which are broadly expressed on most cell types, including leukocytes, IFN-l receptors are largely restricted to cells of epithelial origin. The potential clinical importance of IFN-l as a novel antiviral therapeutic agent is already apparent. In addition, preclinical studies by several groups indicate that IFN-l may also be useful as a potential therapeutic agent for other clinical indications, including certain types of cancer.
We identified a viral IL-10 homolog encoded by an ORF (UL111a) within the human cytomegalovirus (CMV) genome, which we designated cmvIL-10. cmvIL-10 can bind to the human IL-10 receptor and can compete with human IL-10 for binding sites, despite the fact that these two proteins are only 27% identical. cmvIL-10 requires both subunits of the IL-10 receptor complex to induce signal transduction events and biological activities. The structure of the cmvIL-10 gene is unique by itself. The gene retained two of four introns of the IL-10 gene, but the length of the introns was reduced. We demonstrated that cmvIL-10 is expressed in CMVinfected cells. Thus, expression of cmvIL-10 extends the range of counter measures developed by CMV to circumvent detection and destruction by the host immune system. I L-10 is a pleiotropic immunomodulatory cytokine produced by CD4 ϩ and CD8 ϩ T cells, monocytes͞macrophages, keratinocytes, and activated B cells (1). In addition, its expression is elevated in patients with a variety of peripheral blood or bone marrow-derived leukemias, certain B cell and T cell lymphomas and nasal natural killer cell lymphomas and other hematopoietic and solid tumors (1-5). Two mechanisms of IL-10 action can be used by tumors. IL-10 appears to act as an autocrine growth factor for B cell lymphomas. In addition, IL-10 selectively inhibits certain aspects of the cellular immune response. It blocks proinflammatory cytokine synthesis and suppresses the ability of macrophages to serve as antigen-presenting or costimulatory cells (6-8). Thus, IL-10 is a powerful anti-inflammatory agent and a potent immunosuppressor.Many viruses exploit the strategy of using homologs of cellular cytokines or cytokine receptors to shield virus-infected cells from immune defenses and enhance virus survival in the host. The presence of virus-encoded homologs of cellular proteins may be an indicator of the importance of these cellular components in immune mechanisms for combating this virus in vivo. A number of herpes viruses harbor homologs of IL-10. Epstein-Barr virus (EBV)-encoded IL-10 (ebvIL-10), the first viral homolog of IL-10 identified (9, 10), shares many but not all of the biological activities of cellular IL-10 and may play an important role in the host-virus interaction (1,11,12). In addition to EBV, another virus, the Orf poxvirus (OV), which can infect humans, has its own IL-10 homolog, ovIL-10 (13). Whether it is active on human cells remains to be shown. The exact in vivo roles of viral IL-10 homologs in the viral life cycle, in immune evasion, and͞or in helping virus-infected cells to survive immune surveillance remain to be defined.Human cytomegalovirus (CMV) is a widespread herpes virus that is able to persist for decades in its host. CMV is the major cause of a variety of life-threatening diseases in immunocompromised individuals, including transplant and AIDS patients, and is a leading cause of congenital birth defects (14). CMV is also associated with the development of atherosclerosis, restenosis after coronary...
IL-10-related cytokines include IL-20 and IL-22, which induce, respectively, keratinocyte proliferation and acute phase production by hepatocytes, as well as IL-19, melanoma differentiation-associated gene 7, and AK155, three cytokines for which no activity nor receptor complex has been described thus far. Here, we show that mda-7 and IL-19 bind to the previously described IL-20R complex, composed by cytokine receptor family 2–8/IL-20Rα and DIRS1/IL-20Rβ (type I IL-20R). In addition, mda-7 and IL-20, but not IL-19, bind to another receptor complex, composed by IL-22R and DIRS1/IL20Rβ (type II IL-20R). In both cases, binding of the ligands results in STAT3 phosphorylation and activation of a minimal promoter including STAT-binding sites. Taken together, these results demonstrate that: 1) IL-20 induces STAT activation through IL-20R complexes of two types; 2) mda-7 and IL-20 redundantly signal through both complexes; and 3) IL-19 signals only through the type I IL-20R complex.
Recently discovered type III IFNs (IFN-L) exert their antiviral and immunomodulatory activities through a unique receptor complex composed of IFN-LR1 and interleukin-10 receptor 2. To further study type III IFNs, we cloned and characterized mouse IFN-L ligand-receptor system. We showed that, similar to their human orthologues, mIFN-L2 and mIFN-L3 signal through the IFN-L receptor complex, activate IFN stimulated gene factor 3, and are capable of inducing antiviral protection and MHC class I antigen expression in several cell types including B16 melanoma cells. We then used the murine B16 melanoma model to investigate the potential antitumor activities of IFN-Ls. We developed B16 cells constitutively expressing murine IFN-L2 (B16.IFN-L2 cells) and evaluated their tumorigenicity in syngeneic C57BL/6 mice. Although constitutive expression of mIFN-L2 in melanoma cells did not affect their proliferation in vitro, the growth of B16.IFN-L2 cells, when injected s.c. into mice, was either retarded or completely prevented. We found that rejection of the modified tumor cells correlated with their level of IFN-L2 expression. We then developed IFN-L-resistant B16.IFN-L2 cells (B16.IFNL2Res cells) and showed that their tumorigenicity was also highly impaired or completely abolished similar to B16.IFN-L2 cells, suggesting that IFN-Ls engage host mechanisms to inhibit melanoma growth. These in vivo experiments show the antitumor activities of IFN-Ls and suggest their strong therapeutic potential. (Cancer Res 2006; 66(8): 4468-77)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.